Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

19 Citaten (Scopus)


Trials in high-risk melanoma patients evaluating the role of postoperative adjuvant treatment with interferons or other cytokines, ganglioside-based vaccines, or vaccines based on melanoma cells are ongoing or planned internationally. In Europe, the two largest randomised trials are carried out by the European Organization for Research and Treatment of Cancer-Melanoma Cooperative Group (EORTC-MCG). In stage IIA patients (T3N0M0) with a moderate risk of micrometastatic disease (35-40%), Trial 18961 compares observation with ganglioside GM2 vaccination. This trial will be activated during the spring of 1998 and is expected to enrol 1000 patient. In stage IIB-IIIB (T4N0M0-TxN1-2M0) patients with a high risk of micrometastatic disease (approximately 8%), trial 18952 compares observation with adjuvant therapy using two intermediate dosage regimens of interferon alfa-2b (IFNα2b). These trials and the philosophy of the EORTC-MCG programme allow more toxic treatment regimens to be investigated in patients with high-risk disease and only treatments with minimal toxicity to be evaluated in patients with moderate- to low-risk disease. Recently completed and other ongoing trials also are discussed. Overall, if clinical efficacy is demonstrated, the toxicity, impact on quality of life and treatment costs determine the acceptance and applicability of a treatment.

Originele taal-2Engels
Pagina's (van-tot)22-26
Aantal pagina's5
TijdschriftEuropean Journal of Cancer
Nummer van het tijdschriftSUPPL. 3
StatusGepubliceerd - apr. 1998
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit